Analysis and comparison of cohorts of patients with implantable cardioverter- defibrillator in primary and secondary prevention

Česká verzia

Authors: L. Křivan; M. Kozák; M. Sepši; J. Vlašínová; P. Lokaj; J. Špinar
Authors place of work: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jindřich Špinar, CSc., FESC
Published in the journal: Vnitř Lék 2010; 56(2): 99-105
Category: Original Contributions

Summary

Objective:
The aim of this study was an analysis of patients with ICD implanted in primary prevention (PP) in long term follow‑up and comparison with data obtained in secondary prevention patients (SP).

Patients and methods:
We assessed 73 patients with PP ICD and 138 patients with SP ICD. Males were in majority with 88% in PP group and 78% in SP group. The average age was 63 years. Majority of patients suffered from coronary artery disease. The mean ejection fraction (LV EF) was 28% in PP patients and 38% in SP patients. The number of affected coronary arteries and medication were similar in both groups. We compared the occurrence of intercurrent diseases, malignant arrhythmias, inappropriate therapies, hospital readmissions and patients’ survival.

Results:
PP patients had lower LV EF ejection fraction (p < 0.001), higher number of revascularized arteries (p < 0.001) and lower occurrence of inappropriate therapies and arrhythmic storms (p < 0.001). There was higher number of patients with diabetes (p = 0.009), dyslipidemia (p < 0.001) and cerebral artery disease (p = 0.017) among those in PP group. Renal insufficiency was related to a higher risk of death.

Conclusions:
Patients with PP ICD implantation have lower LVEF, and more intercurrent diseases then patients with ICD implanted form SP reasons. Their myocardium is more often revascularized and the occurrence of inappropriate therapy is low. Arrhythmic storm is a typical feature of patients with ICD implanted in secondary prevention.

Key words:
implantable cardioverter‑ defibrillator – primary prevention – secondary prevention – inappropriate therapy – sudden death

Zdroje

1. Mirowski M, Reid P, Mower M et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303: 322– 324.

2. Táborský M. Zásady pro implantace kardiostimulátorů, ICD a SRL. Cor Vasa 2005; 47: 59– 68.

3. Dorian P, Takajíc M, Tang A. Implantable cerdioverter defibrillators for the prevention of sudden death. Can J Cardiol 2005; 21 (Suppl A): 31A– 36A.

4. Goldenberg I, Vyas AK, Hall WJ et al. Risk stratification for primary implantation of a cardioverter defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51: 288– 296.

5. Dorian P, Connolly SJ, Hohnloser SH et al. On behalf of the DINAMIT investigators. Why don’t ICDs decrease all‑cause mortality after MI? Insights form the DINAMIT study. Circulation 2004; 110 (Suppl III): III– 502.

6. Chow T, Kereiakes DJ, Onufer J et al. Does Microvolt T- Wave Alternans Testing Predict Ventricular Tachyarrhythmias in Patients With Ischemic Cardiomyopathy and Prophylactic Defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post‑Myocardial Infarction Patients) Trial. J Am Coll Cardiol 2008; 52: 1607– 1615.

7. Passman R, Kadish A. Sudden death prevention with implantable device. Circulation 2007; 116: 561– 571.

8. Kreuz J, Balta O, Liliegren N et al. Incidence and characteristics of appropriate and inappropriate therapies in recipients of ICD implanted for primary prevention of sudden cardiac death. PACE 2007; 30: S125– S127.

9. Hutyra M, Skála T, Kamínek M et al. Význam stanovení viability myokardu před revaskularizací u pacientů s ischemickou kardiomyopatií a systolickou dysfunkcí levé komory srdeční. Vnitř Lék 2008; 54: 395– 401.

10. Toman O, Poloczek M, Pařenica J et al. Ischemická choroba srdeční s předčasnou manifestací u mladých pacientů. Vnitř Lék 2008; 54: 810– 816.

11. Kenji A, Yoshimitsu S, Masahiko G et al. Long term clinical follow up of japanese heart failure patients received ICD therapy dor primary prevention of sudden cardiac death. J Card Fail 2008; 14: S140– S141.

12. Stiles S. ALTITUDE: Survival with primary prevention ICDs better than ever in remotely monitored „real- world“ population. www.mespe.net/ .../ 01 ICD in primary prevention.pdf.

13. Křivan L, Kozák M, Sepši M et al. Specifické komplikace terapie implantabilními kardiovertery defibrilátory. Čas Lék Čes 2004; 143: 521– 525.

14. Zhi- Jie Z, Drift JB, Gilda WH et al. Sudden cardiac death in the United States, 1988– 1998. Circulation 2001; 104: 2158– 2163.